🇺🇸

US SEC Filing Intelligence

· daily

US IPO Pipeline SEC S-1 Filings — May 06, 2026

The IPO Pipeline stream reveals four S-1 filings dominated by SPAC IPOs, share resales, and post-merger registrations, signaling renewed activity in blank-check companies and secondary offerings amid mixed/neutral sentiments. Futurewave Acquisition Corp launches a $50M SPAC IPO with Nasdaq listing imminent, while Caring Brands and Merlin face dilution from 18.9M and 13.3M share resales respectively, potentially inflating share counts by 3x and fulfilling PIPE rights. SHF Holdings highlights ongoing merger extensions to October 2025 and Series B financing, but no explicit period-over-period financial trends emerge across filings due to pre-revenue SPAC/resale focus. Critical risks include up to $7.73/share dilution at Futurewave and Caring Brands' Nasdaq equity deficiency ($2.09M vs minimum), with compliance due May 22, 2026. Portfolio-level patterns show 3/4 filings involving resale/dilution (avg potential share increase 200%+), contrasting pure SPAC IPO; implications favor short-term trading around listings/compliance but caution on post-IPO redemptions and delisting.

4 high priority 4 total filings
· daily

Global High-Priority Regulatory Events — May 06, 2026

Across 50 filings on May 6, 2026, Q1 2026 results reveal mixed performance with 12/23 10-Q filers showing YoY revenue growth averaging +25% (e.g., AMD +38%, Arista +35%, Lumentum +90%), driven by tech and select financials/energy, but offset by margin compression in 8/23 (-avg 150bps, e.g., Solstice -277bps, Owens Corning gross margin -30%) and losses in materials/healthcare (e.g., HNI swung to -$38.8M, Ultragenyx net loss -23% worse). SPAC/IPO activity surges with 5 new offerings (e.g., Plutonian $100M IPO, Quantum Leap $200M), signaling capital influx into blank checks targeting AI/quantum. M&A catalysts advance positively (Skyworks-Qorvo Phase II China review, late 2026 close; Corebridge-Equitable synergies $500M+), while insolvencies (Tayo Rolls CIRP deadlock) and regulatory actions (Velan Hotels defaults) flag distress. Capital returns robust in 7 firms (e.g., Solstice $0.075 div, YUM $185M buybacks, Bristow $11M treasury), but cash burns rise in biotech (Ultragenyx -$197M ops cash). Portfolio trend: Outperformers in tech/fintech (avg equity +20% QoQ) vs underperformers in energy/materials (avg assets -5% QoQ), with forward guidance stable/reaffirmed in key names positioning for H2 catalysts.

50 high priority 50 total filings
· daily

US Earnings Financial Results SEC Filings — May 06, 2026

Across 50 Q1 2026 filings, mixed sentiments dominate (44/50 mixed or negative), with revenue growth averaging +15% YoY in outperformers like tech (AMD +38%, Arista +35%, Lumentum +90%) but declines in energy (Talos -8%), diagnostics (QuidelOrtho -10.5%), and utilities (Tucson Electric -7.5%); margins compressed in 28/50 companies (avg -150 bps where noted, e.g., Atkore -27% gross profit drop). Net income swung positive in turnaround stories (Taboola + from loss, JBT Marel +$45M from -$173M loss) but widened losses in biotechs (Ultragenyx -23% worse) and amid impairments (Talos $145M charge). Capital returns strong with buybacks (United Therapeutics $1.5B, Arista prior $787M but paused) and dividends (Yum +$0.04/share YoY), though cash piles shrank QoQ in 32/50 (avg -15%). Acquisitions boosted assets (Pinnacle doubled to $122B, Fresh Del Monte +11% QoQ) but integration costs pressured EPS. Portfolio trend: Tech/healthcare M&A active, financials resilient via deals; watch biotech catalysts like Polomar trials (Feb 2026). Implications: Favor tech growth names, avoid margin-squeezed industrials; sector rotation to strong cash flow generators amid capex surges.

50 high priority 50 total filings
· daily

US SEC Trading Suspension Halt Orders — May 06, 2026

Across the single filing in the USA Trading Suspensions stream, Sadot Group Inc. (SDOT) dominates with a critical Form 8-K disclosing a notice of delisting or failure to satisfy continued listing standards under Item 3.01, signaling acute regulatory compliance risks in the restaurant sector (SIC 5810). No period-over-period financial trends, insider activity, forward-looking guidance, capital allocation details, or positive offsets were noted in the enriched data, amplifying the negative sentiment rated 10/10 materiality. This isolated but high-impact event underscores portfolio-level vulnerability to delistings amid US exchange halts, with potential for trading suspension and share value erosion. Item 5.03 hints at governance changes like amendments to articles of incorporation or bylaws, but lacks timelines or bullish catalysts. Investors face immediate bearish implications, including OTC trading risks post-delisting and eroded liquidity. No cross-company trends emerge from the 1-filing sample, but restaurant operators appear prone to listing failures without offsetting metrics like revenue growth or insider buying.

1 high priority 1 total filings
· daily

US Corporate Distress Financial Stress SEC Filings — May 06, 2026

Across 43 filings in the USA Corporate Distress & Bankruptcy stream, financing activities dominate with 25+ companies announcing debt issuances, credit amendments, or equity offerings to enhance liquidity, refinance maturities, or fund growth, signaling proactive balance sheet management amid neutral-to-positive sentiments rather than outright distress. Period-over-period trends show mixed earnings: 6/10 reporting companies posted revenue growth (avg +12% YoY, e.g., Solstice +10%, Texas Pacific +21%), but margins compressed in 4/6 (avg -150 bps, e.g., Solstice -277 bps EBITDA margin), with EBITDA flat/declining in several despite sales beats. Capital allocation leans toward shareholder returns (dividends declared by Solstice, Texas Pacific, Carriage) and buybacks/repurchases (Maplebear $349M, Alkami $100M authorized), while forward guidances are mostly reaffirmed or provided positively (Solstice FY26 sales $3.9-4.1B, Maplebear Q2 GTV +11-13%). True distress signals are sparse (1 delisting notice, 1 payables advance, 1 goodwill impairment), but outliers like Sadot's Nasdaq issues and MSP Recovery's restructuring aid highlight pockets of vulnerability. Sector patterns emerge in energy/real estate (facility expansions, e.g., Permian $3B credit) and tech/pharma (financings for commercialization). Implications: Low systemic distress but watch liquidity-dependent firms; opportunities in refinancings enabling M&A/growth.

43 high priority 43 total filings
· daily

US Executive Officer Management Changes SEC — May 06, 2026

Across 34 filings in the USA Executive & Director Changes stream (May 6, 2026), leadership transitions dominate with 18 CEO/CFO/COO promotions or appointments (e.g., Orrstown, General Mills, Birchtech), 10 departures/retirements (e.g., Anavex CEO, Energy Recovery CEO/CFO), and 6 annual meetings with strong director election support (avg 95%+ for/approval). Period-over-period trends show mixed financials where disclosed: Energy Recovery revenue +20% YoY but gross margins -2750 bps to 27.8%; eHealth revenue -22% YoY but Medicare margins +700 bps to 41%; no broad insider trading but capital allocation positives like Energy Recovery's $25M buyback and Carvana's 1:5 split. Positive sentiment in 12/34 (35%) centers on experienced hires/promotions enhancing strategy (e.g., Hamilton Insurance, Wiley AI focus), while mixed/negative in 7/34 flag risks from sudden exits (Regenerex CFO termination, Anavex CEO departure with 10-Q delay). Portfolio-level pattern: orderly transitions signal continuity in financials/insurance (e.g., Orrstown, RenaissRe), but biotech/healthcare shows churn (Anavex, Bionano, Actuate with going concern). Implications: Bullish for stable firms with internal promotions; monitor biotech for disruption risks amid M&A/innovation catalysts.

34 high priority 34 total filings
· daily

US Corporate Board Director Changes SEC Filings — May 06, 2026

Across 34 filings from May 6, 2026, USA boardroom changes reveal high executive turnover with 12 CEO/CFO transitions (7 appointments, 5 departures), predominantly neutral sentiment (18/34) but tilting positive in financials/insurance (e.g., 95%+ AGM approvals in 6 cases). Period-over-period trends show mixed financial health: revenue growth in 4 firms (Energy Recovery +20% YoY, OEM +65%; eHealth Medicare margins +700bps despite -22% rev; Flutter FY25 +17%) contrasted by sharp declines (Energy Recovery gross margins -2750bps, eHealth net loss widening). Critical developments include sudden CFO terminations/suspensions (Regenerex, Bright Mountain) and interim leadership in biotechs (Anavex, Bionano), signaling potential governance risks amid 3 10-Q extensions/delays. Portfolio-level patterns: Planned retirements/successions (8 cases) outnumber contentious exits (4), with strong shareholder support at AGMs (avg 95%+ approval rates); insurance/financial sectors show board strengthening via experienced adds, while biotechs face leadership voids amid cash concerns. Capital allocation leans retention-focused (e.g., Energy Recovery $25M buyback, comp hikes), but M&A/integration ties (Flora, International Endeavors) flag strategic shifts. Implications: Opportunities in stable transitions, risks in interim-heavy biotechs.

34 high priority 34 total filings
· daily

US Merger & Acquisition SEC Filings — May 06, 2026

The 15 filings reveal a surge in SPAC activity with multiple IPOs (Plutonian $100M, Quantum Leap $200M), unit separations, and deadline extensions (GP-Act III to Nov 2026, Legato to Aug 2026), signaling robust blank check company fundraising amid M&A appetite. Key M&A/takeover highlights include Broadwind's $19.5M facility sale and pivot to precision manufacturing, 908 Devices' NIRLAB acquisition with raised FY2026 revenue guidance to $67-70M (19-25% growth), Nuveen Churchill funds' $347M asset swap, and Brookfield's $1.2B takeover of Peakstone Realty Trust. Period-over-period trends show revenue growth in operating companies (908 Devices +14% YoY to $13.4M, Ascent +9% YoY to $19.4M) but margin pressures (Ascent -272bps to 14.5%, 908 gross +400bps to 51% offset by wider $12M net loss). Mixed sentiments dominate earnings/divestitures, with SPACs neutral-to-positive and compliance risks emerging. Portfolio-level pattern: 7/15 filings involve SPAC lifecycle events, 5 M&A transactions, indicating heightened US takeover activity but with execution risks like high redemptions and guidance withdrawals.

15 high priority 15 total filings
· monthly

US Pre-Market SEC Filings Roundup — May 06, 2026

Overnight SEC filings reveal mixed Q1 2026 earnings across 20+ companies, with healthcare/biotech (e.g., BeOne +35% YoY rev, LivaNova +14.3%) and services (Clear Secure +19.7%, Taboola +9.1%) showing robust revenue growth averaging +15% YoY, while building products (Owens Corning -10%, LP -21%) face sharp declines amid volume/price pressures. Margin trends are divergent: expansions in high-growth names (+720 bps at Clear) contrast compression (-600 bps avg in building materials). M&A momentum builds with Two Harbors CCM deal at 14% premium (meeting May 19), Skyworks-Qorvo Phase II review, and Woori share exchange; SPACs like Quantum Leap ($200M IPO) signal capital inflow. 15+ 13F filings highlight institutional tech overweight (NVIDIA top in 8/15, avg $100M+ positions), implying conviction. Capital returns strong: 10+ dividends declared (e.g., Acushnet $0.255, Deluxe $0.30), buybacks (Life Time $62M, Acushnet $10M). Guidance raised in 8/15 reporters (e.g., BeOne to $6.3-6.5B), cut in 3 (Amcor FCF down), setting Q2 catalysts. Portfolio implication: Rotate from cyclicals to healthcare/tech/services ahead of market open.

18 high priority 32 medium 50 total filings
· daily

Biotech Small-Cap Approvals — May 05, 2026

The May 05, 2026 period captured five 'Other' category (FALLBACK) approvals with neutral investment signals (all strength 5/10, materiality 5/10), comprising 0 NMEs, 0 biosimilars, 0 label expansions per mix breakdown despite individual summaries using 'biosimilar' terminology—suggesting small-molecule generic ANDA approvals. No dominant therapeutic area theme emerges, with products spanning cardiovascular (Propranolol Hydrochloride by IPCA LABS LTD), rheumatology/oncology (Methotrexate Sodium by HETERO LABS LTD VI), ophthalmology (Fluorescein Sodium by BPI LABS), neurology (Pregabalin by UNICHEM), and rare metabolic disorders (Glycerol Phenylbutyrate by LUPIN). Highest-conviction signal is LUPIN's Glycerol Phenylbutyrate approval, a neutral entrant into a narrow rare disease market with undisclosed commercial metrics and no exclusivity details. Key risk/watch item: competitive erosion for originators of these mature molecules and lack of disclosed peak sales/pricing data limits upside assessment.

5 total filings
· daily

New Drug Approvals (Original) — May 05, 2026

The FDA recorded 5 Other approvals in the May 05, 2026 period (dated April 30-May 01), featuring 0 NMEs, 0 biosimilars, 0 label expansions, and 5 neutral signals overall. These fallback approvals granted biosimilar status to PROPRANOLOL HYDROCHLORIDE (IPCA LABS LTD), METHOTREXATE SODIUM (HETERO LABS LTD VI), FLUORESCEIN SODIUM (BPI LABS), PREGABALIN (UNICHEM), and GLYCEROL PHENYLBUTYRATE (LUPIN), spanning cardiovascular, rheumatology/oncology, diagnostics, neurology, and rare metabolic areas with no dominant therapeutic theme. Highest-conviction signal is the neutral (5/10 strength/materiality) biosimilar approval for PREGABALIN by UNICHEM, signaling modest entry opportunity into a mature neuropathic pain market but with NOT_DISCLOSED peak sales and no exclusivity. All approvals carry dual implications: bullish for entrant sponsors via US market access, bearish for unnamed originators via potential erosion, though low materiality tempers impact. Key risk/watch item: pricing competition in commoditized generic/biosimilar segments.

5 total filings
· daily

New Federal Contractors — May 05, 2026

A single high-materiality $242.7M obligation award to FCN, INC. by the IRS's IT Strategy and Modernization office dominates this period's new federal contractors stream, representing 100% civilian spending with zero defense exposure. The firm fixed price delivery order for Broadcom software licenses and maintenance, awarded via full and open competition to the woman-owned small business, shows strong execution with $240.3M already outlayed since December 2022. Highest-conviction bullish signal is FCN's rapid progress on this IT modernization contract, potentially annualizing to $60M in revenue through November 2026. Key risk is high pricing risk inherent to the firm fixed price structure amid rapid outlays nearing full obligation.

1 total filings
· daily

Significant Contract Modifications ($10M+) — May 05, 2026

This digest covers a single significant contract modification totaling $242,713,808 in obligations, entirely civilian with 0/1 defense-related, focused on the Department of the Treasury's IRS IT Strategy and Modernization office. FCN, INC., a woman-owned small business, demonstrates strong execution on a $242M firm fixed price delivery order for Broadcom software licenses and maintenance, with $240M already outlayed since December 2022 toward a November 2026 current end date and $454M potential including options. The highest-conviction bullish signal is FCN's full and open competition win signaling competitive strength in IRS IT modernization. A key risk is high contract pricing risk under the firm fixed price structure, alongside monitoring option exercises and outlay progress beyond $240M.

1 total filings
· daily

Contract Deobligations Alert — May 05, 2026

A single $242,713,808 contract deobligation alert highlights FCN, INC.'s firm fixed price delivery order from the IRS IT Strategy and Modernization office for Broadcom software license and maintenance services, with 0 defense and 1 civilian award. The contract, awarded December 7, 2022, via full and open competition to the woman-owned small business, shows strong execution with $240,260,396 already outlayed toward the $242M obligation and potential ceiling of $454,642,987. The highest-conviction bullish signal stems from rapid progress on this 4-year performance period ending November 30, 2026. A key risk is high pricing risk under the firm fixed price structure, with investors watching option exercise notifications and compliance with the current end date.

1 total filings
· daily

Contract Option Exercises — May 05, 2026

A single $242,713,808 option exercise was recorded for FCN, INC. from the Department of the Treasury's IRS IT Strategy and Modernization office, representing a 100% civilian award with zero defense exposure. This firm fixed price delivery order for Broadcom software license and maintenance services underscores IRS prioritization of IT modernization, with $240,260,396 already outlayed signaling strong execution by the Rockville, MD-based woman-owned small business. The highest-conviction bullish signal is FCN, INC.'s full and open competition win on a contract with $454,642,987 potential including options, implying rapid revenue scaling from an estimated $60M annual base. Key watch item is high contract pricing risk under firm fixed price terms amid the current performance period ending November 30, 2026.

1 total filings
· daily

Federal IT & Cybersecurity Contracts — May 05, 2026

The single contract analyzed represents a $242,713,808 total obligation to FCN, INC. from the IRS's IT Strategy and Modernization office, with 0/1 defense-related (fully civilian Treasury/IRS focus). This firm fixed price delivery order for Broadcom software licenses and maintenance, awarded via full and open competition to the woman-owned small business, signals strong execution with $240,260,396 already outlayed since December 2022. The highest-conviction bullish signal is FCN's rapid progress nearing full obligation payout ahead of the November 30, 2026 current end date, highlighting IRS prioritization of IT modernization. A key risk is high pricing risk under the firm fixed price structure, with investors to watch option exercises toward the $454M ceiling and compliance with the 2026 end date.

1 total filings
· daily

Mega Contracts Monitor ($100M+) — May 05, 2026

The single mega contract in this period totals $242,713,808 in obligations, entirely civilian with zero defense exposure, centered on IRS IT Strategy and Modernization via a firm fixed price delivery order to FCN, INC. FCN, INC., a woman-owned small business, secured this full and open competition win for Broadcom software licenses and maintenance, with $240,260,396 already outlayed signaling strong execution amid a current performance period ending November 30, 2026. The highest-conviction bullish signal is FCN's rapid progress on this $242M obligation (potential $454M with options), highlighting competitive strength in IT application support. A key risk is high pricing/execution risk inherent to the firm fixed price structure, with investors watching option exercises and outlay progress beyond $240M.

1 total filings
· daily

High-Value Federal Grants ($5M+) — May 05, 2026

A single high-value federal grant totaling $242,713,808 was analyzed, representing 0 defense-related and 1 civilian award, dominated by the Department of the Treasury's IRS IT Strategy and Modernization office. FCN, INC., a woman-owned small business, secured this full and open competition firm fixed price delivery order for Broadcom software license and maintenance services, with $240,260,396 already outlayed toward a $454,642,987 ceiling including options. The highest-conviction bullish signal is FCN's strong execution on this nearly fully obligated 4-year contract (Dec 2022-Nov 2026), signaling competitive strength in IRS IT modernization. Key watch item is progress beyond $240M outlays and compliance with the November 30, 2026 end date, amid high pricing risk on the firm fixed price structure.

1 total filings
· daily

General Federal Contracts — May 05, 2026

The single contract analyzed totals $242,713,808 in obligations to FCN, INC. from the Department of the Treasury's IRS, representing a 100% civilian award with no defense exposure. Dominant theme is IRS IT Strategy and Modernization, highlighted by FCN's full and open competition win for Broadcom software licenses and maintenance under a firm fixed price delivery order. Highest-conviction bullish signal is FCN's strong execution with $240,260,396 already outlayed on the $242M obligation, signaling rapid progress toward the November 30, 2026 current end date. Key watch item is option exercises that could expand to $454,642,987 total potential, alongside high pricing risk inherent in the firm fixed price structure.

1 total filings
· daily

S&P 500 Technology Sector SEC Filings — May 05, 2026

Across 28 filings in the S&P 500 Technology stream, core tech names like AMD, Arista Networks, CrowdStrike, Klaviyo, and Salesforce showcase explosive revenue growth averaging 28% YoY (AMD +38%, Arista +35%, Klaviyo +28%, CrowdStrike +22%), fueled by AI/data center (AMD DC +57% to $5.8B) and software expansion (CrowdStrike ARR +24% to $5.25B), with institutional 13Fs from Varma, Factory Mutual, and Illinois MRF confirming mega-cap conviction (NVDA/AAPL tops). Guidance trends bullish with raises at AMD (Q2 rev +46% YoY to $11.2B), Arista (Q2 $2.8B), Klaviyo (FY26 $1.51-1.52B +23-24%), offset by mixed margins (Arista GAAP gross -180bps YoY) and cash flow variability. Capital allocation favors buybacks (Salesforce $50B auth, Klaviyo $500M) over dividends in tech, while non-tech filings (banks/REITs) flag provision surges and debt rises. Portfolio-level: Tech outliers outperform with AI catalysts, but watch leadership churn (Klaviyo CFO exit) and QoQ flats. Implications: Overweight AI enablers; sector growth accelerates amid institutional flows.

12 high priority 16 medium 28 total filings